Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus dexmedetomidine for painless dressing changes in burn patients
ChiCTR2000032305Phase 4Recruiting
- Sponsor
- Shengli Oilfield Central Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and dexmedetomidine in burn injury (2 arms), sponsored by Shengli Oilfield Central Hospital. Primary endpoints: Mean arterial pressure, Heart rate and 2 more. Started May 2020; status: recruiting.
02
Drugs
esketaminedexmedetomidine
03
Conditions
burn injury
Beyond the preview
Go deeper on ChiCTR2000032305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032305.